Paper37540135
Do Imaging Core Laboratories Better Predict Progression Over Clinical Interpretations?
Margolis DJA and 1 other. Radiol Imaging Cancer, 2023. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Do Imaging Core Laboratories Better Predict Progression Over Clinical Interpretations? Papers, record 37540135. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37540135
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics2
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Laboratories | Major topic |
| Diagnostic Imaging | Major topic |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 37540134 | Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations. | https://conductscience.org/library/papers/37540134 |
Source PubMed
References7
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 2 | 37081986 | Predictive power of deep-learning segmentation based prognostication model in non-small cell lung cancer. | Front Oncol | 2023 | https://conductscience.org/library/papers/37081986 | PubMed |
| 3 | 31084479 | Components of Radiologic Progressive Disease Defined by RECIST 1.1 in Patients with Metastatic Clear Cell Renal Cell Carcinoma. | Radiology | 2019 | https://conductscience.org/library/papers/31084479 | PubMed |
| 4 | 12695181 | A radiologist with a ruler... | AJNR Am J Neuroradiol | 2003 | https://conductscience.org/library/papers/12695181 | PubMed |
| 5 | 28825135 | Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria. | J Cancer Res Clin Oncol | 2017 | https://conductscience.org/library/papers/28825135 | PubMed |
| 6 | 33630085 | Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials. | JAMA Netw Open | 2021 | https://conductscience.org/library/papers/33630085 | PubMed |
| 7 | 37540134 | Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations. | Radiol Imaging Cancer | 2023 | https://conductscience.org/library/papers/37540134 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41774133 | Tumor metrics imaging core labs: primer for radiologists. | Abdom Radiol (NY) | 2026 | https://conductscience.org/library/papers/41774133 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37540135
GET https://conductscience.org/api/papers/v1/37540135/authors